Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Current Liabilities (2016 - 2025)

Cytosorbents (CTSO) has disclosed Total Current Liabilities for 14 consecutive years, with $10.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 22.06% year-over-year to $10.1 million, compared with a TTM value of $10.1 million through Sep 2025, up 22.06%, and an annual FY2024 reading of $9.8 million, down 30.0% over the prior year.
  • Total Current Liabilities was $10.1 million for Q3 2025 at Cytosorbents, up from $9.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $14.7 million in Q1 2022 and bottomed at $8.3 million in Q3 2024.
  • Average Total Current Liabilities over 5 years is $10.9 million, with a median of $10.3 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities plummeted 36.22% in 2021, then skyrocketed 50.34% in 2022.
  • Year by year, Total Current Liabilities stood at $13.7 million in 2021, then decreased by 29.04% to $9.7 million in 2022, then soared by 44.48% to $14.0 million in 2023, then dropped by 30.0% to $9.8 million in 2024, then rose by 2.92% to $10.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for CTSO at $10.1 million in Q3 2025, $9.8 million in Q2 2025, and $9.7 million in Q1 2025.